PIK3CA and breast carcinoma: Indeed, a clinical trial testing efficacy of the p110α-isoform-specific inhibitor alpelisib, found that six breast cancer patients harboring PIK3CA mutations displayed initial positive response to treatment until selective pressure promoted acquisition of novel mutations in the tumor suppressor PTEN which associated with metastatic growth and eventually led to treatment failure [54].